ABC2 Fellows Program

We are pleased to announce the launch of our Accelerate Brain Cancer Cure Fellows Program!

The program engages young scientific investigators in the types of issues and discussions that arise in business development and strategic assessment positions within pharmaceutical, biotechnology, financial and philanthropic organizations. The end goal is to enable the Fellows to gain experience and connections that will help them transition into the next phase of their careers.

Two other foundations have joined us in this program: the Chordoma Foundation and the North Carolina Center for the Care of Huntington’s Disease.  In addition, three focused biotechnology companies are participating: Agile Sciences, Theralogics and a brand new cancer diagnostics start-up, ProtoDia. 

The combination of foundations, venture philanthropy organizations and focused drug discovery and development companies will offer our Fellows an opportunity to work closely with the leadership of these organizations to investigate and analyze issues of real strategic importance. 

Meet our first three Fellows and learn about the scientific, clinical, business and strategy questions they are investigating:

Jason Reeves

Jason Reeves is a graduate research assistant in the Program in Genetics and Genomics at Duke University.

Jason is focusing on analysis of developing interventions for low and high grade gliomas. He has analyzed the landscape of current immunological treatments, as well as virally mediated treatment of brain cancers.  Jason is also assisting to develop a workshop focusing on low-grade gliomas.

Lu Huang

Lu Huang is a graduate research assistant in the Counter Lab in the Department of Pharmacology and Cancer Biology at Duke University.

Lu is studying literature on the use of Ipilumimab as a first line therapy immediately following the first resection of a newly diagnosed tumor.  She is also looking into similar or analogous approaches from other cancers.  The thinking is that immediate use of Ipilumimab may make it possible to impact the tumor via the still mostly intact immune system.

Felicia Hawthorne

Felicia Hawthorne is a Ph.D. candidate and a Human Genetics and Genomics graduate research assistant at Duke University.

Felicia is working on a project for Agile Sciences. Agile has discovered a new class of small organic compounds that inhibit bacterial resistance. They want to test their compounds in the best in-vivo models of resistant bacterial infection.  Felicia researched the field to gain an understanding of what models and strains existed, prepared a summary of the literature for the specific bacterial strains and infection models, and provided insights into the ideas of Agile's proposal and provided opinions on areas for improvements or modifications.

Newsletter Issue: 
Share |
August 11, 2014 12:27 PM
Drs. Maria Castro and Pedro Lowenstein, both of the U-M Department of Neurosurgery, co-led the research.
July 25, 2014 10:51 AM
Guest blogger Lisa Peabody shares her personal story and her experience as an advocate at the recent Alliance for Childhood Cancer Action Day.
July 3, 2014 11:01 AM
ABC2 helped fund the early-stage research by Dr. Andrew Parsa that is now being developed by Agenus.

Join us in our fight for a cure!